Advanced Regenerative Support for Optic Neuropathy in India
Targeted cellular therapy protocols designed to support optic nerve cellular health, microcirculation, and functional stabilization.
What It Is
An autologous/allogeneic mesenchymal stem cell (MSC) procedure focused on delivering neurotrophic and anti-inflammatory support directly to compromised optic pathways.
Primary Objective
Slowing or halting progressive vision decline, supporting surviving retinal ganglion cells, and enhancing cellular repair mechanisms.
Patient Eligibility & Screening Criteria
Thorough neurological and ophthalmic criteria guiding patient qualification
Indications Evaluated:
- • Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
- • Leber’s Hereditary Optic Neuropathy (LHON)
- • Traumatic or Toxic Optic Neuropathy
- • Post-Neuritis Optic Nerve Atrophy
Key Requirements:
- • Documented diagnosis with recent OCT (Optical Coherence Tomography), VEP (Visual Evoked Potential), and visual field tests.
- • Baseline medical fitness for travel and outpatient/short-stay clinical protocols.
- • Preserved viable axonal tissue (cells cannot regenerate completely severed or necrotic tracts).
Reported Potential Improvements & Clinical Goals
Outcomes vary depending on optic nerve atrophy severity, chronicity, and baseline visual acuity.
Disease Stabilization
Primary therapeutic goal of mitigating further irreversible nerve fiber loss.
Patient Experience: Stem Cell Therapy for Optic Nerve Damage | Patient from UK
Watch this clinical case study demonstrating observed visual field preservation, light sensitivity, and optic nerve rehabilitation outcomes at Stem Cell Therapy Center India.
Why Choose Our Center in India?
World-class neuro-ophthalmic facilities, fellowship-trained surgical faculty, and ethical protocols
Accredited Centers
Internationally Accredited Centers: Procedures conducted in JCI/NABH-accredited facilities adhering to cleanroom stem cell processing standards.
Multi-Disciplinary Care
Experienced Multi-Disciplinary Care: Co-managed by senior neuro-ophthalmologists, vitreoretinal surgeons, and regenerative biologists.
Cost Efficiency
Cost Efficiency: Comprehensive clinical packages at 60%–70% lower costs than comparable centers in the US, Europe, or UK.
Transparent Case Selection
Transparent Case Selection: Rigorous pre-screening; our medical panel only accepts cases where therapeutic rationale exists.
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering single or bilateral eyes based on clinical severity and cell dosage).
(Aimed at slowing visual degeneration, neurotrophic rescue, and stabilizing functional sight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | $4,500 – $7,500 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $25,000 – $45,000 USD | 3 – 6 Months | Clinical Trial Gated |
| United Kingdom & EU | $22,000 – $38,000 USD | 2 – 5 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $32,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated International Patient Services
End-to-end guidance from international case triage to return flight clearance
Complimentary Medical Triage
Complimentary Medical Triage: Remote pre-travel document review and preliminary treatment roadmap.
Medical Visa Assistance
Medical Visa Assistance: Official hospital invitation letters and visa processing guidance.
Language Support
Language Support: Multi-lingual coordinators (English, Arabic, Russian, French, and Spanish).
Private Logistics
Private Logistics: Chauffeur-driven airport transfers and daily clinic transit.
Post-Discharge Care
Post-Discharge Care: 12-month structured telemedicine follow-ups and coordination with your local ophthalmologist.
Logistics, Travel & Accommodation
Smooth transit, companion support, and comfortable hotel partner arrangements
Stay Arrangements
Stay Arrangements: Direct booking assistance with 4-star and 5-star partner hotels or serviced suites near the hospital.
Companion Friendly
Companion Friendly: Executive inpatient suites with dedicated patient attendant amenities.
Local Amenities
Local Amenities: International cuisine options, currency exchange, and 24/7 dedicated guest relations manager.
Treatment Protocol & Typical Schedule (5–7 Days)
Structured clinical milestones throughout your medical journey in India
Day 1: Arrival & Clinical Assessment
Airport pickup, hospital admission, in-person neuro-ophthalmology consultation, baseline imaging (OCT/VEP), and bloodwork.
Day 2–3: Cellular Administration
Administration of targeted stem cell infusions (retrobulbar, targeted peribulbar, or intravenous routes under sterile surgical conditions).
Day 4: Supportive Therapies
Hyperbaric Oxygen Therapy (HBOT), neuroprotective IV infusions, and visual rehabilitation guidance.
Day 5–7: Post-Procedure Monitoring & Discharge
Slit-lamp examination, discharge summary compilation, travel clearance, and home follow-up schedule.
Cellular Quality Release & Procedural Safety Standards
ISO Class 5 certified cleanrooms, rigorous sterility cultures, and ophthalmic safety monitoring
cGMP Cleanroom Processing
Cellular processing in Grade A biosafety laminar airflow cabinets with continuous particulate monitoring.
Flow Cytometry Verification
ISCT mesenchymal phenotype verified: ≥95% CD73/CD90/CD105 expression and ≤2% hematopoietic markers.
14-Day Sterility Release
Complete sterility testing against aerobic/anaerobic bacteria, fungi, mycoplasma PCR, and LAL endotoxin testing.
Institutional Ethics Approval
Protocols guided by Institutional Ethics Committees (IEC) registered with CDSCO, Government of India.
Frequently Asked Questions: Optic Neuropathy Care
Authoritative medical guidance regarding cellular protocols, realistic visual outcomes, and travel
Candidates include patients with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), Leber's Hereditary Optic Neuropathy (LHON), post-neuritis optic atrophy, and chronic traumatic optic neuropathy with residual light perception (Weiss & Levy, 2018).
Stem cell therapy cannot regenerate an optic nerve that has completely withered or suffered full transection. Its primary therapeutic action is neurotrophic rescue: releasing BDNF, CNTF, and VEGF to reactivate dormant, surviving axonal bundles and suppress scar tissue formation.
Objective metrics include Visual Evoked Potentials (VEP P100 wave latency and amplitude), OCT measurement of peripapillary retinal nerve fiber layer (RNFL) thickness, and automated Goldman/Humphrey field charting.
Senior ophthalmic surgeons perform targeted retrobulbar, peribulbar, or sub-Tenon infusions directly adjacent to the optic nerve sheath, frequently paired with intravenous infusion for microvascular collateral enhancement.
Procedures use small, calibrated micro-volumes administered under local topical anesthesia. Intraocular pressure (IOP) and orbital tension are closely monitored with zero documented incidence of retrobulbar compartment syndrome in our partner hospitals.
Many patients observe changes in color perception, contrast distinction, and peripheral light sensitivity within 6 to 12 weeks, with electrophysiological stabilization continuing over 6 to 12 months.
Peer-Reviewed Scientific Citations & Clinical References
Key published clinical trials and peer-reviewed literature supporting cellular therapy in Optic Neuropathy:
Regulatory & Medical Disclaimer
Important Medical Notice:
Stem cell therapies for optic neuropathy are considered emerging regenerative treatments. Clinical outcomes differ significantly by patient based on etiology, age, and nerve damage duration. These therapies do not guarantee complete vision restoration or an absolute cure. In India, regenerative protocols operate under ethical research and therapeutic application standards governed by the Indian Council of Medical Research (ICMR) and relevant national statutory authorities. Prospective patients are advised to review risks, realistic expectations, and alternative options with their primary physician.